Results 251 to 260 of about 192,172 (285)

A reduction in serum IFN-γ, IL-1β, IL-6, and GM-CSF serves as potential markers for a positive outcome to lumbar epidural steroid injections. [PDF]

PLoS One
Chalermkitpanit P, Singhatanadgige W, Yingsakmongkol W, Tanasansomboon T, Jitjumnong M, Honsawek S.   +5 more
europepmc   +1 more source

GM-CSF-mediated epithelial-immune cell cross-talk orchestrates pulmonary immunity to <i>Aspergillus fumigatus</i>. [PDF]

Sci Immunol
Mills KAM, Westermann F, Espinosa V, Rosiek E, Desai JV, Aufiero MA, Guo Y, Liu FL, Mitchell KA, Tuzlak S, De Feo D, Lionakis MS, Rivera A, Becher B, Hohl TM.   +14 more
europepmc   +1 more source

Elevated nitric oxide during colitis restrains GM-CSF production in ILC3 cells via suppressing an AhR-Cyp4f13-NF-κB axis. [PDF]

Nat Commun
Zhao X, Li J, Zhang Y, Hu L, Wu D, Wu J, Lyu R, Li P, An G, Cui R, Sun T, Zhu P, Bai L, Jiang C, Zhong C.   +14 more
europepmc   +1 more source

High-altitude hypoxia exacerbates chemotherapy-induced myelosuppression by lowering serum G-CSF/GM-CSF and regulating apoptosis and proliferation. [PDF]

Discov Oncol
Shi J, Zhao F, Qiu T, Ren D, Li Z, Ma J, Zhao J.   +6 more
europepmc   +1 more source

Synergistic effects of cryoablation and GM-CSF in colorectal liver metastases management in tumor-bearing mice. [PDF]

Iran J Basic Med Sci
Wang J, Kong D.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice

American Journal of Physiology-Lung Cellular and Molecular Physiology, 1999
Surfactant proteins and phospholipids accumulate in the alveolar spaces and lung tissues of mice deficient in granulocyte-macrophage colony-stimulating factor (GM-CSF), with pathological findings resembling the histology seen in the human disease pulmonary alveolar proteinosis (PAP).
J A, Reed, M, Ikegami, E R, Cianciolo, W, Lu, P S, Cho, W, Hull, A H, Jobe, J A, Whitsett   +7 more
openaire   +2 more sources

Incidence of GM-CSF Antibodies in Cancer Patients Receiving GM-CSF for Immunostimulation

Clinical Immunology, 2001
We have assessed the immunogenicity profile of GM-CSF in patients with either colorectal carcinoma (CRC) at different stages of disease or with multiple myeloma who were given recombinant human GM-CSF (Escherichia coli-derived) combination therapy. Metastatic CRC patients received a colon carcinoma-reactive antibody and high doses of GM-CSF (425--500 ...
G, Ullenhag, C, Bird, P, Ragnhammar, J E, Frödin, K, Strigård, A, OIsterborg, R, Thorpe, H, Mellstedt, M, Wadhwa   +8 more
openaire   +2 more sources

GM‐CSF and phorbol esters modulate GM‐CSF receptor expression by independent mechanisms

Journal of Cellular Physiology, 1991
AbstractHuman granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) (0.1 nM) down‐modulates its receptor in IL‐3/GM‐CSF dependent M‐07e cells, in KG‐1 cells and normal granulocytes, whereas phorbol esters 12‐O‐tetradecanoylphorbol‐13‐acetate (TPA) (2 nM) down‐modulates the GM‐CSF receptor in M‐07e cells and granulocytes but not in KG‐1 cells.
BRIZZI, Maria Felice, Arduino C, Avanzi GC, BUSSOLINO, Federico, PEGORARO, Luigi   +4 more
openaire   +3 more sources

GM-CSF in marrow transplantation

European Journal of Cancer, 1993
Bone marrow transplantation (BMT) is being increasingly used in a wide variety of diseases. During the period of re-engraftment the patient is particularly susceptible to a number of opportunistic infections which can radically affect acute morbidity and mortality.
openaire   +2 more sources